Elevance Health, Inc. Stock: price and insider trades · United States · SEC (Form 4)

About Elevance Health, Inc.

Elevance Health, Inc. is a leading U.S. health insurer and healthcare services company listed on the NYSE under the ticker ELV. Formerly known as Anthem, the company rebranded to Elevance Health to better reflect a broader business model that goes beyond traditional insurance. Headquartered in Indianapolis, Indiana, it operates primarily in the United States and combines managed health benefits with care delivery support, pharmacy services, behavioral health, and data-driven healthcare solutions. The group serves a diverse base of customers, including employers, individuals, government-sponsored members, and Medicare/Medicaid populations depending on state contracts and program participation. Its business is commonly described through two major platforms: Health Benefits, which covers the core insurance and managed care franchise, and Carelon, the services arm that provides care coordination, pharmacy, behavioral health, and analytics capabilities. This structure gives Elevance Health exposure both to premium revenue and to service-oriented, potentially more scalable healthcare workflows. From a competitive standpoint, Elevance Health ranks among the top tier of U.S. managed care organizations. Its market position is supported by scale, broad provider relationships, deep employer and public-program penetration, and an increasingly integrated approach to healthcare management. The company has also invested heavily in digital tools such as the Sydney Health app and virtual assistance features to simplify access, improve member navigation, and strengthen engagement across the care journey. In parallel, it promotes value-based care partnerships and provider recognition programs to improve quality and control costs. Recent developments suggest a business focused on execution, technology, and cost discipline. In second-quarter 2025, Elevance Health reported growth in operating revenue and raised its full-year adjusted EPS guidance, while noting higher medical cost trends in some lines of business. In 2026, the company continued to highlight digital expansion, provider-network initiatives, and leadership changes aimed at strengthening execution across its platforms. For French-speaking investors, ELV remains a defensive U.S. healthcare name with attractive structural characteristics, but it is also sensitive to medical cost inflation, reimbursement trends, and regulatory developments in the United States.